VeriStrat helps you make more informed treatment decisions.
Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are an effective, targeted therapy for advanced non-small cell lung cancer (NSCLC), but not all patients benefit from treatment.1 Identifying appropriate patients for therapy is key to improving patient outcomes. Several molecular tests and clinical factors are currently utilized to help identify patients who may derive benefit from EGFR-TKI therapy.2
VeriStrat is a unique, proteomic test that uses matrix assisted laser desorption/ionization time of flight (MALDI-TOF) mass spectrometry (MS) to reliably characterize protein content in pre-treatment serum samples. VeriStrat identifies patients who are likely to have good or poor outcomes following treatment with EGFR-TKI therapy and is intended to be used for patients with advanced NSCLC who have progressed after first line therapy.3 Results of the VeriStrat test are independent of patient characteristics, such as histology, gender, ethnicity, smoking history and genetic mutational status (EGFR and KRAS).4
Using only a simple blood draw, this non-invasive, pre-treatment serum test typically provides results in less than 72 hours – enabling you to make a timely and more informed decision regarding your patients’ therapy options.
References
1. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005;353:123-132.
2. Herbst RS, Sandler A. Bevacizumab and Erlotinib: A Promising New Approach to the Treatment of Advanced NSCLC. The Oncologist. 2008;13:1166-1176.
3. Taguchi F, Solomon B, Gregorc V, et al. Mass spectrometry to classify non-small-cell lung cancer patients for clinical outcome after treatment with epidermal growth factor receptor tyrosine kinase inhibitors: a multicohort cross-institutional study. J Natl Cancer Inst. 2007;99:838-846.
4.Carbone D, 2nd European Lung Cancer Conference, April 2010.
